<DOC>
	<DOCNO>NCT00788151</DOCNO>
	<brief_summary>This trial evaluate use tetravalent vaccine dengue . Primary Objectives : - To describe immune response dengue vaccination dengue vaccine two age cohort child previously vaccinate yellow fever ( YF ) vaccine - To evaluate safety vaccination dengue vaccine two age cohort child .</brief_summary>
	<brief_title>Study ChimeriVax™ Tetravalent Dengue Vaccine Healthy Peruvian Children Aged 2 11 Years</brief_title>
	<detailed_description>The control group receive two dos placebo one dose Pneumo 23 vaccine third vaccination</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Severe Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Inclusion Criteria : Aged 2 11 year day inclusion . Subject good health , base medical history , physical examination laboratory parameter . Provision Assent Form sign subject ( subject ≥8 year old ) Informed Consent Form sign parent another legally acceptable representative ( independent witness illiterate parent [ ] ) . Subject parents/legally acceptable representative able attend schedule visit comply trial procedure . For female subject childbearing potential ( girls postmenarche ) , avoid become pregnant ( use effective method contraception abstinence ) least 4 week prior first vaccination , least 4 week last vaccination . Documented receipt yellow fever vaccine since least one month first vaccination . Exclusion Criteria : Personal family history thymic pathology ( thymoma ) , thymectomy , myasthenia . For female subject childbearing potential ( girls postmenarche ) , know pregnancy . For female subject childbearing potential ( girls postmenarche ) , know pregnancy positive pregnancy test blood sample take Screening . Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination . Planned participation another clinical trial trial . Known suspected congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy . Known systemic hypersensitivity vaccine component history lifethreatening reaction trial vaccine vaccine contain substance . Systemic hypersensitivity YF vaccine history lifethreatening reaction YF vaccine . Chronic illness stage could interfere trial conduct completion , opinion Investigator . Current past alcohol abuse drug addiction may interfere subject 's ability comply trial procedure . Receipt blood bloodderived product past 3 month , might interfere assessment immune response . Receipt vaccine 4 week precede first trial vaccination . Planned receipt vaccine 4 week follow first trial vaccination . Human Immunodeficiency Virus , hepatitis B antigen , hepatitis C seropositivity blood sample take Screening . Clinically significant laboratory abnormality ( determined Investigator ) blood sample take Screening . Known previous vaccination pneumococcal polysaccharide vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Dengue virus</keyword>
	<keyword>Dengue fever</keyword>
	<keyword>Dengue hemorrhagic fever</keyword>
	<keyword>Dengue disease</keyword>
	<keyword>Dengue vaccine</keyword>
</DOC>